Therapeutic Targeting of miR-21 Restores SASH1 and Sensitizes HBV-HCC to Sorafenib
The miR-21/SASH1 axis play a critical role in sorafenib resistance in HBV-associated HCC, and targeting miR-21 may provide a promising therapeutic strategy to enhance treatment efficacy.
Authors
- Ryunjin Lee
- Gi‐Won Song (ORCID: https://orcid.org/0000-0002-4235-0434)
- Eunkyeong Lee (ORCID: https://orcid.org/0000-0002-2106-2169)
- Dong‐Hyuk Jung (ORCID: https://orcid.org/0000-0002-3411-0676)
- Suhyeon Ha
- Eun‐Kyoung Jwa (ORCID: https://orcid.org/0000-0003-4820-0039)
- Kyuyoung Han
- Young‐In Yoon (ORCID: https://orcid.org/0000-0002-9308-0366)
- Sung‐Gyu Lee (ORCID: https://orcid.org/0000-0001-9161-3491)
- Jiye Kim (ORCID: https://orcid.org/0000-0002-5758-6810)
- Hye Ok Kim (ORCID: https://orcid.org/0000-0002-3899-7710)
- Eunyoung Tak (ORCID: https://orcid.org/0009-0005-1556-5180)
- Hyunhee Kwon
- Shin Hwang
- Seoon Kang
- Tae Won Kim
- Gil-Chun Park
- Jung-Man Namgoon
Institutions
- Ulsan College (KR)
- Asan Medical Center (KR)
- Kyung Hee University (KR)
- University of Ulsan (KR)
Publication Details
- Journal
- Cancers
- Published
- 2026-03-23
- DOI
- https://doi.org/10.3390/cancers18061038
- Primary Topic
- RNA regulation and disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00